Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Searches For CEO, Appoints Flavell To Board

Premium

NEW HAVEN, Conn.--Jonathan Rothberg, chairman of the board of CuraGen, said he has begun a search for a president and chief executive officer for the company. "CuraGen has been experiencing tremendous growth through its recent collaborations, technological advancements, and scientific progress," Rothberg said. "Given our increasing momentum in the marketplace, I desire a partner at the helm of the company to complement my scientific skills as a leader of a large and rapidly growing business," he added. In the past year, the 300-person company, which was founded by Rothberg in 1993, has discovered more than 60,000 human genetic variations; signed a pharmacogenomics deal with Glaxo Wellcome; issued a patent on its GeneCalling technology; and announced a comprehensive product discovery and development collaboration with Hoffmann-La Roche.

CuraGen also recently appointed Richard Flavell, chairman and professor of immunobiology at Yale University, to its scientific advisory board. Flavell is also an investigator at Howard Hughes Medical Institute.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.